CLVS Clovis Oncology Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 03 March 2020 Clovis Oncology to Present at the Barclays Global Healthcare Conference

   Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March 10, 2020 at 11:15 a.m.

2. 02 March 2020 Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain

   Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib

3. 24 February 2020 Clovis Oncology Announces 2019 Operating Results

   Rubraca® (rucaparib) net product revenue totaled $143.0M for 2019 and $39.3M for Q4 2019 Net product revenue for 2019 up 50% over 2018 46% reduction in net cash utilized in 2H 2019 compared to 1H 2019 $296.7M

4. 13 February 2020 Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24

   Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis' senior management will host

5. 11 February 2020 Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference

   Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26,

6. 03 February 2020 Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

   Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib

7. 15 January 2020 Clovis Oncology's Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer

   - Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer - FDA submission based on data from TRITON clinical program

8. 07 January 2020 Clovis Oncology Announces Debt Refinancing Transaction

   Clovis Oncology, Inc. (NASDAQ:CLVS) (the "Company") announced today that on January 6, 2020 it priced a registered direct offering (the "Share Offering") of an aggregate of 17,777,679 shares (the "Shares") of its common

9. 07 January 2020 Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019

   Estimated $38.3M - $39.3M in Rubraca® sales for Q4 2019 and $142.0M-$143.0M for FY2019 consistent with guidance Q4/FY2019 Operating Results call planned for

10. 16 December 2019 Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium

    Presented at the International Symposium on Theranostics/Precision Oncology (ICPO) FAP-targeted images consistent with those of PET and CT scans Encouraging tumor accumulation and retention in initial

11. 13 November 2019 Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy

    Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib

12. 07 November 2019 Clovis Oncology Announces Third Quarter 2019 Operating Results

    $37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year Net product revenue increased 14% sequentially in Q3 2019 compared to Q2 2019, including sequential U.S. sales increase of 12%

13. 22 October 2019 Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7

    Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its third quarter 2019 financial results on Thursday, November 7, 2019, before the open of the U.S. financial markets. Clovis' senior management will host a conference

14. 11 October 2019 Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

    Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through

15. 29 September 2019 Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

    43.9% confirmed objective response rate (ORR) in 57 RECIST*-evaluable patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1/2 mutation 52.0% confirmed prostate-specific antigen (PSA)

16. 23 September 2019 Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

    Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals Clovis currently planning to

17. 12 September 2019 Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

    Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Exploratory ARIEL3 analysis for Rubraca maintenance treatment regimen in

18. 28 August 2019 Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference

    Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 8:35 AM

19. 22 August 2019 Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024

    Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the initial purchasers of the previously announced offering of the Company's 4.50% Convertible Senior Notes due 2024 (the "notes") in a private placement to